Q-omics provides the consensus-scored PNPT1 profile across patient tissues and cancer cell-line models. PNPT1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PNPT1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, PNPT1 protein abundance shows 36,216 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where PNPT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNPT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNPT1 survival associations across molecular data types. PNPT1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNPT1 RNA expression–survival associations across cancer types. High PNPT1 expression shows unfavorable associations in ACC, LIHC, UCEC, KICH, PAAD and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PNPT1 RNA expression.
This table summarizes PNPT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 12. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PNPT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNPT1 shows lower tumor expression in THCA and higher tumor expression in BLCA, HNSC, LUAD, COAD and LIHC. The BLCA box plot shows higher PNPT1 RNA expression in tumor versus normal tissue (log2 FC = +0.988, t-test p < 0.001).
This table shows molecular features associated with PNPT1 in patient tissues and cancer cell lines. In patient samples, PNPT1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PNPT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
